Chimeric Halts CHM-2101 Trial After Safety Review, Shifts Focus To Preclinical Approach
CHM: $0.003 +0.00% · MC: $442K
Chimeric Therapeutics stopped enrolment and dosing in its CHM-2101 trial after a safety review found the highest tested dose unsafe and trial events triggered the protocol’s stopping rules; the company says it will not progress the treatment in its current form despite preliminary signs of anti-tumour activity. It is proposing a preclinical in vivo CDH17 programme, with animal feasibility work dependent on additional funding, and says cost reductions are expected to lower annualised expenditure by approximately $4 million. The supplied excerpt is truncated and does not include the full cash-flow details.

Comments